Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab

OBJECTIVES: COVID‐19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T‐cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers mu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Immunology
Main Authors: Caballero, Armando, Filgueira, Lázaro M, Betancourt, Julio, Sánchez, Naivy, Hidalgo, Carlos, Ramírez, Alberto, Martinez, Alejandro, Despaigne, Rolando E, Escalona, Alberto, Diaz, Henrry, Meriño, Elio, Ortega, Lilia M, Castillo, Ulises, Ramos, Mayra, Saavedra, Danay, García, Yanelda, Lorenzo, Geydi, Cepeda, Meylán, Arencibia, Maylén, Cabrera, Leticia, Domecq, Milagros, Estévez, Daymys, Valenzuela, Carmen, Lorenzo, Patricia, Sánchez, Lizet, Mazorra, Zaima, León, Kalet, Crombet, Tania
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7688906/
https://ncbi.nlm.nih.gov/pubmed/33304584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1218
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados